+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phase II trial of recombinant beta interferon in advanced colorectal cancer



Phase II trial of recombinant beta interferon in advanced colorectal cancer



Cancer Treatment Reports 71(10): 965-967



Betaseron is a genetically altered recombinant beta interferon with in vitro properties equivalent to those of native beta interferon. Nineteen patients with measurable advanced colorectal carcinoma who had no previous chemotherapy were given 30 X 10(6) IU Betaseron by iv push on Days 1-5 and 8-12 of each 28-day cycle. One of 17 evaluable patients had a complete response after nine courses of treatment which has been sustained greater than 9 months. The overall response rate was 6% (95% confidence limits, 0%-18%). Treatment was well tolerated with toxic effects consisting of fever, flu-like symptoms, nausea and vomiting, and transient mild granulocytopenia and liver function abnormalities. All toxic effects were World Health Organization (WHO) grade less than or equal to 2. No interferon neutralizing antibody activity was detected. Phase I and preclinical data support further investigation of Betaseron with dose escalation to tolerance for individual patients, as well as investigation of concomitant therapy with 5-fluorouracil, in an attempt to improve the observed response rate in colorectal cancer.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 040964479

Download citation: RISBibTeXText

PMID: 3308080


Related references

Open-label phase II trial of recombinant beta interferon (IFN-beta (ser)) in patients with colorectal cancer. Cancer Treatment Reports 71(10): 983-984, 1987

Phase ii clinical trial of human recombinant gamma interferon in patients with advanced colorectal cancer. Proceedings of the American Association for Cancer Research Annual Meeting 27: 181, 1986

Phase II trial of recombinant DNA gamma-interferon in advanced colorectal cancer: a Southwest Oncology Group study. Journal of ImmunoTherapy 10(5): 379-382, 1991

Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer. Anti-Cancer Drugs 10(6): 519-524, 1999

A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer. British Journal of Cancer 80(5-6): 786-791, 1999

Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma. Cancer Research 50(7): 2056-2059, 1990

A phase II study of recombinant interferon-beta in combination with 5-fluorouracil in the treatment of patients with advanced colorectal carcinoma. British Journal of Cancer 75(3): 423-426, 1997

Recombinant gamma interferon in advanced breast cancer: a phase II trial. Investigational new Drugs 4(4): 377-381, 1986

Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. Journal of Clinical Oncology 9(10): 1806-1810, 1991

Recombinant DNA human interferon alpha 2 in advanced breast cancer: a phase 2 trial. British Journal of Cancer 51(1): 55-60, 1985

A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer. British Journal of Cancer 74(6): 971-974, 1996

Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer. International Journal of Colorectal Disease 2(1): 26-29, 1987

Phase I study of recombinant human interferon beta in patients with advanced cancer. Journal of Biological Response Modifiers 6(2): 121-129, 1987

Recombinant leukocyte A interferon in advanced breast cancer. Results of a phase II efficacy trial. Annals of Internal Medicine 98(5 Pt 1): 598-602, 1983

A phase I trial with recombinant interferon gamma (Roussel UCLAF) in advanced cancer patients. Cancer Immunology ImmunoTherapy 32(1): 67-70, 1990